MedTrace Logo

Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients

NCT06576102 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 204

Last updated 2025-03-27

No results posted yet for this study

Summary

Spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent SARS-CoV-2 infection within a population of hematology patients with humoral immunity deficiency.

Conditions

  • Persistent COVID-19
  • B Cell Malignancies

Interventions

OTHER

Persisting SARS-CoV-2 infection

Prevalence of persisting SARS-CoV-2 infection among immunocompromised patients defined as the persistence or the recurrence of symptoms and signs (fever, dyspnea, hypoxemia, changes on chest-X ray or CT scan) and positive SARS-CoV-2 PCR ≥ 21 days after the time 0 (day of the first test positive for SARS-CoV-2 infection)

Sponsors & Collaborators

  • Maddalena Giannella

    lead OTHER

Principal Investigators

  • Maddalena Giannella, MD PhD · University of Bologna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-09-30
Completion
2025-09-30

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06576102 on ClinicalTrials.gov